摘要
依据卫生部新近制定的《生物材料和制品的生物学评价标准》(简称《标准》)[1],确定五项评价项目,按照标准的生物学试验方法,对目前临床应用的羟基磷灰石制品进行系统研究。结果表明:国产羟基磷灰石制品除有轻微细胞毒性外,其致敏性、溶血性、致突变性和组织相容性均符合《标准》要求,临床应用安全。
According to 'The standards for biological evaluation of bio materials and bio products abbreviated to STANDARDS” newly set by the Ministry of Health,PRC,5 observation indexes were selected to evaluate systematically the biocompatibility and toxicology of China made hydroxyapatite,which is clinicall used.The results revealed no effects of allergy,mutation and hemoclasis reaction except mild cytotoxicity.These indicate that the China made hydroxyapatite meets the demand of STANDADS and thus may be clinically with safety.
出处
《生物医学工程学杂志》
EI
CAS
CSCD
北大核心
1998年第1期28-31,共4页
Journal of Biomedical Engineering